Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 2 (CTDSP2) is a nuclear phosphatase enzyme that specifically dephosphorylates the Ser-5 residue in the C-terminal domain (CTD) repeats of RNA polymerase II, thereby regulating RNA polymerase II activity and gene transcription. CTDSP2 plays a multifunctional role, influencing cell proliferation, matrix remodeling, and transcriptional regulation, including both direct impact on cell cycle checkpoints through Ras signaling and p21 upregulation, as well as modulation of TGF-β/SMAD signaling and extracellular matrix production. It is implicated in oncogenic processes, possibly acting as a tumor suppressor, and interacts with pathways relevant in cancer and renal disease. No drugs directly targeting CTDSP2 are approved, but its function and regulation (such as by miR-26a) have been linked to disease mechanisms in solid tumors and metabolic disorders[1][2][3].
Inhibition or modulation of phosphatase activity (predictive, as no approved drugs are currently listed)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 2 (CTDSP2).